FIGURE 10.

KLF13 overexpression protects cardiomyocytes from cell death and DNA degradation triggered by doxorubicin. HL-1 cells were transfected with a KLF13 plasmid and treated with Dox for 48 h. A, representative Western blotting showing KLF13 protein levels in HL-1-transfected cells. Control (empty vector), GFP (control for transfection efficiency), and KLF13 plasmid are shown. B, percentage (%) of dead cells in control and KLF13 overexpressing cells. C, percentage (%) of degraded DNA in each group treatment. Data represented as the mean ± S.E. from three independent experiments. **, p < 0.01; ***, p < 0.001; ns, no significant.